Get the Stockscreener App
6.89
1.47%
0.10
After Hours:
7.04
0.15
+2.18%
Overview
News
Price History
Option Chain
Financials
Why BHC Down?
Discussions
Forecast
Stock Split
Dividend History
Bausch Health Companies Inc stock is traded at $6.89, with a volume of 1.18M.
It is up +1.47% in the last 24 hours and up +7.99% over the past month.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
See More
Previous Close:
$6.79
Open:
$6.79
24h Volume:
1.18M
Relative Volume:
0.56
Market Cap:
$2.54B
Revenue:
$9.47B
Net Income/Loss:
$-178.00M
P/E Ratio:
-14.35
EPS:
-0.48
Net Cash Flow:
$1.01B
1W Performance:
-4.44%
1M Performance:
+7.99%
6M Performance:
+9.02%
1Y Performance:
-25.75%
1-Day Range:
$6.6659
$6.92
1-Week Range:
$6.6659
$7.3307
52-Week Range:
$3.96
$11.46
Bausch Health Companies Inc Stock (BHC) Company Profile
Name
Bausch Health Companies Inc
Sector
Phone
514-744-6792
Address
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Compare BHC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHC
Bausch Health Companies Inc
|
6.89 | 2.54B | 9.47B | -178.00M | 1.01B | -0.48 |
|
ZTS
Zoetis Inc
|
160.06 | 71.67B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 47.44B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.19 | 46.08B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.46 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.36 | 13.97B | 612.78M | -86.37M | -62.91M | -0.87 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-02-24 | Downgrade | Piper Sandler | Neutral → Underweight |
| Jul-10-24 | Initiated | Raymond James | Mkt Perform |
| Sep-20-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Jul-29-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-29-22 | Downgrade | Truist | Buy → Hold |
| Jul-28-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-13-22 | Resumed | JP Morgan | Overweight |
| Mar-24-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-17-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-22-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-17-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-24-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-24-20 | Initiated | Citigroup | Buy |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-22-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-02-19 | Initiated | Goldman | Neutral |
| Oct-25-19 | Initiated | Cowen | Outperform |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Aug-15-19 | Upgrade | TD Securities | Hold → Buy |
| Jul-19-19 | Initiated | Wolfe Research | Outperform |
| Jun-11-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Jan-02-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Nov-05-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-13-18 | Upgrade | Piper Jaffray | Underweight → Neutral |
View All
Bausch Health Companies Inc Stock (BHC) Latest News
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Microkeratome Market Detailed In New Research Report 2025 | - openPR
Overt Hepatic Encephalopathy Treatment Market: Key - openPR
Bausch Health Companies Inc. (NYSE:BHC) Receives $7.42 Consensus PT from Analysts - Defense World
Cosmetic Surgery Market Forecast Report and Company - GlobeNewswire
Cosmetic Surgery Market Forecast Report and Company Analysis 2025-2033 Featuring AbbVie, Cutera, Sientra, Bausch Health, Johnson & Johnson, Apyx Medical, Hologic, Merz Pharma, Galderma, Cynosure - Yahoo Finance
Actinic Keratosis Market Is Booming Worldwide 2025-2032 | - openPR
Bausch Health projects $4.95B-$5.1B revenue for 2025 with focus on growth and innovation - MSN
Scar Treatment Market Projected To Witness Massive Growth, - openPR
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Bausch Health Companies Inc.(BHC) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Bausch Health Companies Inc. (BHC): Among Top Stock Picks From Carl Icahn’s Portfolio - Insider Monkey
Bausch Health Companies: Stocks Overvalued by Analyst Consensus on TSX (BHC) - The Globe and Mail
Bausch Health Plans $5 Billion Debt Sale to Tackle Liabilities - Yahoo Finance
Blepharitis Market on Track for Major Expansion by 2034, - openPR
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R) - ACCESS Newswire
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R) - ACCESS Newswire
Is Bausch Health Companies Inc. (BHC) the Best Low Price Pharma Stock to Invest In Right Now? - Insider Monkey
Coulter Partners Recruits Chief Medical Officer for Bausch Health - Hunt Scanlon Media
Acute Repetitive Seizures Market Booming with Advanced - openPR
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales - MSN
Bausch Health Companies (NYSE:BHC) Releases Quarterly Earnings Results, Misses Expectations By $0.44 EPS - MarketBeat
Van ECK Associates Corp Sells 119,848 Shares of Bausch Health Companies Inc. (NYSE:BHC) - Defense World
Bausch + Lomb: Solid 2024 Results, But Let's Address The Elephant In The Room (BLCO) - Seeking Alpha
Bausch Health Companies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Why Bausch Health Companies Inc. (BHC) Went Up On Thursday? - Yahoo Finance
Bausch Health Q4 Earnings Recap (Reiterating Buy Rating) (NYSE:BHC) - Seeking Alpha
‘New’ B+L? Wait Until Bausch Health Sells Stake - News & Insights
Alibaba, Hasbro, Shake Shack, Bausch Health And Other Big Stocks Moving Higher On Thursday - Benzinga
Toronto Stocks Slip; Bausch Health Shares Climb on 4Q Beat, Rosy 2025 Outlook -February 20, 2025 at 12:24 pm EST - Marketscreener.com
Bausch Health Companies Inc. (NYSE:BHC) Q4 2024 Earnings Call Transcript - Insider Monkey
Bausch Health Companies Inc. SEC 10-K Report - TradingView
BAUSCH HEALTH COMPANIES INC. (NYSE:BHC) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Bausch Health Companies Inc. - ACCESS Newswire
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises - MSN
Bausch: Q4 Earnings Snapshot - The Washington Post
Bausch Health Reports Strong 2024 Financial Performance - TipRanks
Bausch Health Companies Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Compared to Estimates, Bausch (BHC) Q4 Earnings: A Look at Key Metrics - Nasdaq
Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates - Nasdaq
Bausch Health Swings to Q4 Profit, Revenue Increases -- Shares Rise After Hours -February 19, 2025 at 05:27 pm EST - Marketscreener.com
Bausch Health Reports Strong 2024 Financial Results with Continued Growth - TipRanks
Bausch Health Shares Climb On Better-Than-Expected Q4 Revenue, Strong Forward Guidance - Benzinga India
Bausch Health Announces Fourth Quarter and Full-Year 2024 Results - Galveston County Daily News
Can Bausch Health's 7-Quarter Growth Streak Signal a Healthcare Sector Momentum Shift? - StockTitan
Bausch & Lomb aims to shake up contact lenses with deal off the table - Yahoo Finance UK
Bausch and Lomb's dealmaking CEO Brent Saunders: No deal for company is imminent - Yahoo Finance
Bausch Health Companies Q4 2024 Earnings Preview - MSN
Revenues Working Against Bausch Health Companies Inc.'s (NYSE:BHC) Share Price - Simply Wall St
Bausch Health Companies Inc Stock (BHC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.77%
0.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):